Rankings
▼
Calendar
KNSA FY 2018 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
FY 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$286,000
Operating Income
-$108M
Net Income
-$103M
EPS (Diluted)
$-3.49
Cash Flow
Operating Cash Flow
-$81M
Free Cash Flow
-$86M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$322M
Total Liabilities
$43M
Stockholders' Equity
-$194M
Cash & Equivalents
$307M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$286,000
-$28,000
-921.4%
Operating Income
-$108M
-$65M
-65.4%
Net Income
-$103M
-$65M
-59.1%
← Q4 2017
All Quarters
Q1 2018 →